timothy sykes logo
ORIC Pharmaceuticals Faces Turbulence Amid Prostate Cancer Drug Advancements Thumbnail
ADD US ONG Google News

ORIC Pharmaceuticals Faces Turbulence Amid Prostate Cancer Drug Advancements

MATT MONACO•UPDATED APR. 2, 2026, 11:32 AM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

Oric Pharmaceuticals Inc.’s stocks have been trading up by 11.17% following promising news on pipeline progress.

Candlestick Chart

Live Update At 11:32:13 EDT: On Thursday, April 02, 2026 Oric Pharmaceuticals Inc. stock [NASDAQ: ORIC] is trending up by 11.17%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Looking at recent market data, ORIC Pharmaceuticals exhibited notable fluctuations. Their stock, once trading around $12.67 at the end of March, slid drastically to around $7.475 a day later. This steep drop is largely attributed to investor anxiety following the announcement of upcoming Phase 3 trials for their prostate cancer treatment, rinzimetostat. The drug, paired with darolutamide, promises great potential, yet early discontinuations draw parallels with existing competitors, causing market jitters.

In financial terms, despite an enterprise value of about $468.69M, the firm struggles with negative profitability ratios. ORIC’s financials reflect high operational and research expenses, outstripping its revenues and resulting in continuous losses. The current ratio of 14.1 highlights liquidity strength, but with no long-term debt, the firm has limited leverage options.

Market Reactions

In the investing world, news can be both a blessing and a curse. ORIC’s latest drug enhancement announcements initially seemed promising, but market reactions painted a different picture. Investors, familiar with the routine rises and falls of the healthcare sector, saw a stark 20–25% plunge following updates of Phase 1 results for rinzimetostat combined with darolutamide.

This reaction isn’t purely emotional; it’s rooted in performance comparisons with established pharmaceutical giants like Pfizer. In such a scenario, equity analysts frequently play savIOR. While Wedbush trimmed ORIC’s price target, they maintained an outperform rating, hinting at enduring optimism.

Moreover, stock market ebbs and flows echoed analyst insights urging stakeholders to “buy the dip.” Citi noted the dip as overdone, suggesting a rebound may soon follow, hinting at long-term growth potential once market concerns subside.

More Breaking News

Conclusion

Navigating through market ebbs and flows, ORIC Pharmaceuticals stands at a pivotal moment. Recent updates on their prostate cancer drug, coupled with price volatility, create both challenges and opportunities. As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” This reminder is crucial for traders observing ORIC, as the news of upcoming large-scale trials assures stakeholders of ORIC’s commitment to innovation but brings necessary short-term unpredictability.

In conclusion, while financial metrics display a story of struggle, strategic drug development advancements present a beacon of hope. As market forces react and recalibrate, the company’s emphasis on clinical successes and safety may eventually redefine its standing within the fiercely competitive pharmaceutical arena.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ORIC

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”